Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: In contrast to the substantial body of clinical trial evidence, the real-world evidence regarding the efficacy of statins in the prevention of cardiovascular events among patients with type 2 diabetes mellitus (T2DM) is relatively limited. Therefore, we assessed the effectiveness of atorvastatin for the primary prevention of CV events in patients with T2DM, using a population-based data in South Korea.
Methods And Results: This retrospective cohort study was conducted using the National Health Insurance Service Customized Database (2008-2018) in South Korea. We identified atorvastatin users and statin non-users with T2DM without history of cancer or CV events. The two groups were matched using propensity scores. The association between CV events and atorvastatin was estimated using an extended Cox model with the Heaviside function (split at 3 years). We identified 41 024 atorvastatin users and 41 024 statin non-users (mean age: 58.1 and 58.2 years, respectively). The incidence rate and case fatality rate of CV events were higher in statin non-users than in atorvastatin users. Atorvastatin significantly reduced the risk of CV events after 3 years of treatment (hazard ratio [HR]: 0.98 (95 % confidence interval: 0.90-1.05) and 0.76 (0.72-0.80) within and after 3 years, respectively). The HR for stroke was lower than that for coronary heart disease.
Conclusion: In real-world patients with T2DM without a history of CV events, atorvastatin was associated with a decreased risk of CV events after 3 years of treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.numecd.2024.10.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Experience from Türkiye: Genetic and Therapeutic Insights in Pediatric Heterozygous Familial Hypercholesterolemia.
J Clin Res Pediatr Endocrinol
August 2025
Ege University Faculty of Medicine, Department of Pediatrics, Division of Metabolism and Nutrition, İzmir, Turkey.
Objective: Familial hypercholesterolemia (FH) is an inherited metabolic disorder that increases cardiovascular risk from childhood. Despite its frequency, pediatric diagnosis and treatment remain inadequate, particularly in developing countries.
Methods: We retrospectively analysed 124 pediatric patients with genetically confirmed heterozygous FH (HeFH).
Effects of Statin Therapy on Glycemic Control and Associated Factors Among Type 2 Diabetes Mellitus Patients in Northeastern Tanzania: A Retrospective Cohort Study.
J Diabetes Res
August 2025
Department of Internal Medicine, KCMC University, Moshi, Tanzania.
Statins have been implicated in poor glycemic control among patients with diabetes mellitus (DM), prompting the US Food and Drug Administration (FDA) to update warning labels on all statins to reflect the risk of increased blood glucose levels. However, few studies from sub-Saharan Africa have assessed this concern. This study investigated the effects of statins on glycemic control among patients with Type 2 diabetes mellitus (T2DM) in Kilimanjaro, northeastern Tanzania.
View Article and Find Full Text PDFEffect of LDL-Cholesterol Levels and Oral Atorvastatin on Outcomes After Pipeline Therapy for Intracranial Aneurysms.
Stroke
August 2025
Neurovascular Center, Engineering Research Center of Diagnostic and Therapeutic Technology and Devices for Cerebrovascular Diseases, Ministry of Education, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China (X.F., C.H., Z.W., M.H., J.L., J.H., H.Y., A.X., G.M., R.G
Background: We aimed to determine the effects of statin treatment on outcomes of pipeline embolization device therapy for intracranial aneurysms in relation to LDL (low-density lipoprotein) cholesterol levels.
Methods: Using data from the SESIA registry (Safety and Efficacy of Stent Deployment for Intracranial Aneurysms), we enrolled participants who underwent pipeline embolization device implantation at 4 centers in China (2018-2022). Statin users (atorvastatin 20 mg daily, for ≥3 days and ≥6 months preprocedurally and postprocedurally, respectively) were matched with nonstatin users (1:1) using propensity scores and further adjusted by inverse probability of treatment weighting, balancing for baseline characteristics, procedural details, and lipid levels (based on East Asian profiles).
Comparison of treatment patterns, efficacy and safety between generic and branded atorvastatin users in China: a multicenter, retrospective propensity score-matched cohort study.
Lipids Health Dis
July 2025
Department of Pharmacy, Xuanwu Hospital of Capital Medical University, 45 Changchun Street, Xicheng District, Beijing, 100053, China.
Background: To evaluate and compare the treatment patterns, effectiveness, and safety of generic and branded atorvastatin in China.
Methods: This multicenter, retrospective cohort study collected and analyzed data from patients who initiated atorvastatin therapy for the first time across 16 hospitals between 2020 and 2022. Treatment patterns included adherence, persistence, switching, augmentation.
Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis.
Indian J Endocrinol Metab
June 2025
Department of Rheumatology, Center for Endocrinology Diabetes Arthritis and Rheumatism Superspeciality Healthcare, New Delhi, India.
Introduction: Fenofibrate forms the standard of care for managing hypertriglyceridemia. Many of these patients have associated metabolic dysfunction-associated steatotic liver disease (MASLD). No systematic review and meta-analysis (SRM) has analysed the impact of fenofibrate in MASLD.
View Article and Find Full Text PDF